The selection was conducted by a high-level expert selection team, taking into account the multi-dimensional perspectives of the scientific, industrial, investment, medical and regulatory sectors, and invited the notary department to conduct the whole process of notarization. Finally, the projects with forward-looking, unique, leading and malleability were selected. The award-winning enterprises can receive support in 10 aspects, including clinical resources, supervision and guidance, intellectual property, and research and development support.

About novamab

Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd., located in Shanghai International Medical Park, Pudong New Area, Shanghai, is a clinical stage company dedicated to the research and development of innovative drugs for nano-antibody. Luoqi Bio-pharmaceutical has a high-level foundation for the research and development of nano-antibody drugs, has established an integrated, systematic and comprehensive professional development platform, and is the only company in China with the ability to develop nano-antibody drugs in the whole process. Loki Biological has built a 500L Pichia pastoris nanoantibody GMP pilot production workshop, filling the industry gap in this field, which is extremely scarce and competitive.

At present, Rocky Biology has many new drug product chains of nanoantibodies, covering respiratory diseases, autoimmune diseases, tumors and other fields. Among them, LQ036, the world's first inhaled macromolecular asthma treatment drug for respiratory diseases, entered the phase I clinical trial in Australia in June 2021, and human experiments showed excellent safety; In January 2022, the Chinese clinical phase I IND of the project has also been officially approved, and the Chinese clinical phase I will be carried out simultaneously. In addition, LQ043, an innovative drug for respiratory diseases, has also been submitted to the domestic Pre-IND.